Petros Pharmaceuticals, Inc. (PTPI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Fady Boctor.
PTPI tiene fecha de IPO 2020-12-02, 18 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $180.73K.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
